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 Treating afflictions of the central nervous system (CNS) is particularly 
challenging and increasingly necessary. According to the Centers for Disease Control 
and Prevention, malignant neoplasms (cancer), cerebrovascular diseases (stroke), 
death in the United States [1]. Malignant neoplasms include all forms of cancer, but of 
particular concern to the CNS is malignant glioma, a difficult to treat form of cancer 
[2]. Although this number is small relative to the incidences 
of cancer affecting other parts of the body, brain and nervous system cancers are less 
treatable than other cancers. Surgical removal of brain tumors is insufficient treatment, 
as malignant glioma cells are capable of moving beyond the edge of the tumor mass 
into the parenchyma. The cells are left behind in the brain, leading to recurrence of the 
tumor. 
 Diseases affecting the brain require innovative treatments, as the brain is 
protected by the blood-brain barrier (BBB). Materials in the bloodstream are 
prevented from directly entering the brain by the presence of endothelial tight 
junctions, which prevent all but the smallest molecules (<400 Da) from entering 
passively. In addition, brain endothelial cells have transporter proteins that can 
selectively transport compounds from the brain interstitium to the bloodstream.  
Larger molecules can move across the BBB using carrier-mediated transport [3], but 
this mechanism is reserved for particular molecules needed to maintain homeostasis. 
While some research focuses on exploiting receptor-mediated transport or hiding 
small therapeutic molecules from efflux transport proteins [4,5], there are other 
methods for circumventing the BBB [6] that present novel means for treating CNS 
disease. Of particular interest is the technique of convection-enhanced delivery (CED), 
in which materials are directly infused into brain tissue.  
 Glioma treatments currently employ a combination of tumor removal by 
surgical resection and subsequent treatment with radiation, including, sometimes, 
implantation of a chemotherapeutic drug [7,8] to treat migrating cells beyond the 
resection cavity. The chemotherapeutic drug is incorporated in polymeric Gliadel ® 
wafers, which can be introduced directly into the resection cavity following surgery. 
Transport of the drug contained in the wafers, bischloroethylnitrosourea (BCNU), into 
the surrounding tissue relies on diffusion. The concentration gradient between the drug 
reservoir and the tissue allows the drug molecules to diffuse into the parenchyma. 
Once in the parenchyma, the BCNU passively diffuses throughout the adjacent tissue 
and may reach and destroy tumor cells in the local area. However, recurrence of the 
tumors is still an issue [9], despite the Gliadel® treatment showing clinical efficacy 
[10,11]. Diffusive transport of BCNU combined with various clearance mechanisms 
that can remove drugs from the brain parenchyma are likely culprits for tumor 
recurrence. Clearance mechanisms include transport across blood vessel walls into the 
bloodstream, enzymatic degradation, biotransformation, binding to cell membranes, 
and incorporation into non-target cells. In order to effectively prevent recurrence, a 
therapeutically useful concentration of the drug must penetrate into the parenchyma to 
reach migrating malignant cells. It is these clearance mechanisms, in addition to mass-
transfer issues in the extra cellular spaces (ECS), which play critical roles in limiting 
the drug from getting to its desired destination. 
 To overcome the diffusive limitations of treating malignant gliomas, 
convection-enhanced delivery (CED) has been developed as a means of improving the 
overall distribution of drug molecules in the brain. This technique is not significantly 
more invasive than the current treatments, as it is employed for infusing therapeutics 
directly into tumors and after the tumor has been removed via surgery. Bobo et al. 
used this technique in vivo to deliver macromolecules into the feline brain [12]. Their 
worked showed increased distribution of large molecules using CED compared with 
diffusive transport alone. CED has been studied for use with a number of different 
infusates for treatment of different CNS diseases [13 16]
no enhancement [17] to significant efficacy when delivered alongside conventional 
treatments [18 20].  
 In principle, convection should aid in increasing distribution of the infused 
drug, which should lead to a higher probability of the drug reaching targets that cannot 
be reached by diffusive transport. Without a detailed examination of the spatial 
distribution of the infusate once injected, it is difficult to assess why efficacy is not as 
good as theory predicts it should be. Simulation and modelling has been studied to 
predict infusion patterns [21 23]. To study the behavior of materials introduced 
directly into the parenchyma, research has been done using gel phantoms [24 26]. 
Agarose gels of either 0.2% or 0.6% concentration were used to predict infusion 
patterns for given flow rates or catheter design. While modelling and in vitro methods 
can help influence design of clinical procedures, they do not fully predict the behavior 
of materials once introduced in vivo. To fully understand the mechanisms that govern 
transport phenomena during a CED-like infusion, direct imaging is necessary. Post-
mortem image analysis of CED in tissue slices excised from rodents gives insights 
into overall infusate distribution [13,18,20,27 29]. Nuclear magnetic resonance 
(NMR) imaging allows for real-time imaging of the infusate during CED infusions in 
various animal models [24,28,30,31]. Post-mortem analysis gives the investigators a 
view of the overall infusate distribution near the termination of the animal. NMR gives 
location data for the infusate at different times during the infusion, but often lacks 
small-scale resolution for determining micron-scale motion. 
 Interest in micron-scale motion of the infused material has gained importance 
due to discoveries indicating that transport of fluid in the brain may be enhanced in the 
perivascular spaces (PVS) surrounding blood vessels [32,33]. PVS are thin regions 
outside blood vessels in the brain. During CED, it is possible that the infused materials 
have access to these paths [34]. Evidence suggests that these paths may present less 
resistance to flow than that presented by interstitial pathways [32,33]. The infused 
material varies from experiment to experiment, but nanoparticles have gained interest 
in recent years due to their ability to encapsulate large amounts of therapeutics and to 
deliver therapeutics over time within the brain [6]. 
 To investigate the movement of nanoparticles during a CED-like infusion, we 
present a technique for sampling the infusate with high spatial and temporal 
resolution. This technique involves the use of two-photon microscopy, a fluorescence 
imaging method that allows for deeper tissue penetration and a well-defined focal 
volume [35,36]. By oscillating a motorized stage while observing two-photon 
fluorescence, we can elucidate transport properties of nanoparticles while they are 
infused. The unparalleled resolution allows for accurate determination of distribution 
volume, parenchymal velocity, and perivascular velocity. We can identify PVS 
entrances for nanoparticle efflux from the infusion site, and observe how local PVS 
influence the infusate cloud morphology. By varying particle size and type, we can 
observe how the ECS mean pore size influences particle movement. With a deeper 
understanding of particle dynamics, CED can be further improved for therapeutic 
purposes, as we can predict where the particles will go with greater accuracy. We 
believe this knowledge can be used to influence further research and clinical practice 
for better treatment of CNS diseases. 
 Chapter 2 details the development of the imaging technique used in this work. 
By performing a craniotomy on an anesthetized rat and imaging in our oscillatory 
fashion, we can observe particle movement in real time. This chapter also covers the 
algorithm development for processing the raw image stacks and the process for 
extracting various quantitative features from the images. We discuss how we came to 
the parameters used for the studies shown in Chapter 3. This chapter contains various 
output images that give weight to the assertion that high resolution images of the 
infusate being delivered in real time are necessary for understanding what actually 
occurs during a CED-like infusion. Finally, we discuss the drawbacks of this system, 
which include the finite imaging depth involved with fluorescence imaging. 
 Chapter 3 describes experimental results. With the imaging setup discussed in 
Chapter 2, we aimed to characterize the infusions of various infusates similar to those 
used in the literature. We infused four sizes of fluorescently-tagged polystyrene beads 
and three sizes of fluorescent liposomes. We also ran infusions using an infusate 
composed of a fluorescent, lower molecular weight dextran and polystyrene beads. We 
were able to determine that smaller particles traveled further than larger particles for a 
given amount of time of infusion. The volume of distribution for the polystyrene beads 
was significantly lower than that of the liposomes of comparable size. The hindrance 
on the larger particles for both the polystyrene beads and the liposomes leads to lower 
volumes of distribution for each. The velocity of the infused material propagating 
from the infusion site for the various infusates dropped rapidly as the infusion 
progresses. The smaller infusates maintained a higher velocity than the larger infusates 
at greater penetration distances. All infusates entered perivascular spaces. For the 
larger infusates, the proportion of particles in the perivascular space relative the 
particles in the parenchyma was markedly higher on average for the larger particles. 
The larger infusates could move further from the point of infusion due to the presence 
of these perivascular spaces. We discuss the quantitative results and present theories 
for the influences of perivascular transport on the distribution of therapeutics during a 
CED infusion. We discuss interesting behavior, such as the presence of micro-
channels in the parenchyma allowing movement of larger particles, which seem to 
lead to perivascular spaces. These findings are discussed in the context of the literature 
in this area. 
 Chapter 4 departs from the two-photon imaging, and discusses agarose gel 
experimentation done to model the interface between different regions of the brain (or 
different sections of tissue). By preparing an agarose gel layer of lower concentration 
on a second layer of higher concentration, and infusing near the location where the 
two layers meet, we were able simulate infusions near an interface. The material 
properties of the different concentration gels on either side of the interface lead to 
reduced concentration of the infusate in the higher concentration gel. The penetration 
distance of the infusate into the higher concentration gel was also reduced, further 
reinforcing the role that porosity and mean pore size play in allowing transport of 
therapeutics in vivo. While agarose gel experimentation cannot fully simulate an in 
vivo infusion into living tissue, it can act as a guide before moving to animal and 
clinical experimentation. 
 Chapter 5 briefly discusses the context of this work and recommendations for 









 There are two ways to investigate therapeutic material transport in vivo. The 
first is to infuse materials tagged with some marker that can be viewed post-mortem to 
elucidate where the materials went during the infusion. This method generally 
involves sacrificing the animal immediately after the infusion, and sectioning the brain 
to view cross-sections of the infused material. Bobo et al. infused In-labelled 
transferrin into anesthetized cats to investigate the effect of convection on increasing 
the distribution volume of infused materials [12]. MacKay et al. investigated the 
effects of particle charge, particle diameter, and steric coating of liposomes on their 
overall distribution and penetration depth following a CED infusion [27]. Hamilton et 
al. co-infused heparin with various proteins to show that heparin was capable of 
increasing distribution volume relative to protein infusion alone [13].  
 The second way to elucidate the transport behavior of the materials during a 
CED-like infusion is to image the infusate as it is being introduced into the tissue. The 
most common method of this technique involves using magnetic resonance imaging 
(MRI). A tracer molecule, such as gadolinium, is introduced into the tissue while the 
MRI setup images the region of the tissue. The recorded images contain location data 
of the infused material. From this location data, the volume occupied by the infusate, 
or volume of distribution (VD), of the infused material is reconstructed from the data. 
Kim et al. infused gadolinium-labelled-
dorsal and ventral hippocampus as part of a dynamic contrast-enhanced MRI 
experiment. They showed that the marker preferentially travelled along anatomy with 
less fluid resistance [37]. Richardson et al. infused gadoteridol with adeno-associated 
virus serotype 2-glial-derived neurotrophic factor into the putamen and thalamus of 
monkeys. They were able to accurately reconstruct the distribution volume, as well as 
correlate the gadoteridol signal with GDNF expression, indicating therapeutic efficacy 
[38]. Haar et al. observed gadolinium-
diethylenetriamine pentaacetic acid as tracer infused during CED using MRI to study 
the differences between behaviour of the infusate under normal and ischemic 
conditions [31]. All of these, and the majority of other MRI-monitored CED infusions, 
rely on temporal resolutions of minutes to tens of minutes for a single volume 
sampling, with voxel size on the order of 0.1-1 mm3. Therefore, the behavior that is 
being studied via MRI is a macroscopic view of the infused materials. 
 While viewing infused materials macroscopically can lead to clinical 
prediction of therapeutic efficacy and enhanced targeting for various CNS treatments, 
anatomical mechanisms that affect the overall behaviour of the infused material occur 
on the micro and nano-length scales. The average effective pore size in the 
extracellular spaces (ECS) is predicted to be between 38 and 64 nm [39] for healthy 
tissue, and diffusion experiments using PEG-coated nanoparticles suggest that glioma 
ECS spacing is even smaller [40]. More recent experiments have shown through real-
time multiple particle tracking that nanoparticles greater than100 nm in diameter are 
capable of penetrating human and rat tissue [41]. Further investigations using multiple 
particle tracking have shown that nanoparticles between 100 and 200 nm are capable 
of moving through roughly one fourth the pores in an area of the tissue. However, 
nanoparticles larger than 200 nm are extremely hindered in their motion, which 
suggests pores or pathways are not large enough to accommodate larger particles [42]. 
Furthermore, there is an additional mode of transport once a therapeutic is introduced 
into the parenchyma. The brain contains fluid clearance systems that carry materials 
away from the desired destination [43,44]. It is these clearance systems, in addition to 
the intrinsic hindered transport through the ECS, which play critical roles in limiting 
the drug from getting to its desired destination. 
 Research into the purpose and function of perivascular routes in the brain has 
increased dramatically in recent years. Perivascular spaces (PVS) had been detailed by 
research since at least the 1970s [45,46]. These compartments are extensions of the 
subarachnoid space that encompass brain vasculature, creating thin (micron scale at 
capillary level) annular regions. Pulsations of the blood vessel walls may help to 
propel fluid in the PVS [32,47 49]. The PVS have been shown as part of a functioning 
glymphatic
et al. [43]. This system is believed to play a role in fluid movement-related systems in 
the brain, such as metabolite clearance [50], tau aggregation following traumatic brain 
injury [51], and removal/accumulation of amyloid- [52]. Given the prevalence of 
blood vessels throughout the brain, the PVS should also play a role in clearance of 
infused materials during CED.  
 Two-photon excitation fluorescence (2PEF) microscopy is a novel technique 
for investigating the microscale movements of infused particles in the brain. In 
conventional fluorescence imaging, scattering of photons in the biological tissue 
prevents collection of the fluorescence beyond surface imaging of the sample. Higher-
photon imaging modalities, such as 2PEF microscopy, allow for greater imaging 
depths to be achieved, as scattering of the photons in the biological tissue is greatly 
reduced. This allows for capturing of imaging planes within the biological tissue down 
to depths of 1 mm. 2PEF microscopy has been used to observe astrocyte/blood vessel 
anatomy [53], investigate age-related differences in cerebral capillary blood flow [54], 
and, most relevant to this work, capture images of perivascular transport during CED 
in the rat cortex [33]. Previous work in our lab had shown particles moving through 
the parenchyma and the PVS at vastly different speeds by watching a plane above the 
point of infusion using this 2PEF technique. 
In this study, we developed a platform for imaging the distribution volume of 
various infusates using two-photon fluorescence microscopy. A live anesthetized rat is 
placed on a continuously oscillating motorized stage. Fluorescence is captured in two-
dimensional planes throughout various depths in the tissue while an infusate is 
delivered into the rat cortex. This yields compilations of images at the recorded depths 
image stacks, the location of the infusate in the cortex is tracked over the course of the 
infusion, allowing for real-time observation of the movement of the infusate. With this 
information, it is possible to show the infusate morphology (also referred to as cloud 
morphology) at various points in the infusion with unrivaled spatial and temporal 
resolution. The development of this platform allows for in vivo characterization of 
various infusates at the microscale, allowing for an unprecedented look at where 
therapeutic-like particles go during a CED-like infusion. 
 
2.2 Materials and Methods 
 
2.2.1 Rat Craniotomy Procedure 
 
Adult male Sprague-Dawley rats (weighing 250-450 g) were anesthetized via 
isoflurane inhalation (1 % in oxygen at 0.2 L/min). Animals were secured in a 
stereotactic frame and an incision was made in the skin along the dorsal midline. Skin 
and muscle tissue were excised to reveal a ~3 cm section of the skull. A dental drill 
was used to open a ~1 cm circular craniotomy, exposing the brain from near the 
midline to the right side of the skull. A 30 gauge needle was used to make a small 
incision in the dura, and a fine hook was then used to pull back the dura to the outer 
portions of the craniotomy. Once bleeding near the craniotomy had ceased, fluorescein 
isothiocyanate (FITC) conjugated to 2-MDa dextran (Sigma-Aldrich, St. Louis, MO) 
was administered directly to the bloodstream via tail vein injection. FITC, once in the 
bloodstream, labels the blood plasma, allowing for visualization of the vasculature in 
the brain using 2PEF. A glass coverslip was placed over the craniotomy and fixed to 
the skull using dental cement. All animal procedures were performed in accordance 
with the Cornell University Institutional Animal Care and Use Committee guidelines 
and regulations. 
 2.2.2 Imaging Setup 
 
 To observe the proliferation of infused materials into the rat cortex, we 
employed a technique using a custom-built microscope setup. To collect emitted 
fluorescence from the infused materials at multiple depths within the rat cortex, the 
animal was moved toward and away from the microscope objective continuously over 
the course of the infusion. Therefore, the recorded images are two dimensional scans 
of various depths within the rat cortex. The scans occur at discrete times, meaning the 
compilation of recorded images from a single up and down motion of the motorized 
stage, or loop, is both spatially and time dependent. The compilation of recorded 
 
 An example of the imaging setup can be found in Figure 2.1. The rat was 
placed on a 3-axis motorized stage beneath the optics (shown without objective in  
Figure 2.1). A micromanipulator was fixed on the stage near the rat. A plastic rod 
held the infusion needle in place on the micromanipulator. Rigid plastic tubing was 
fixed to the non-injecting end of the needle, with the other end attached to the syringe 
beneath the stage. The syringe was held in place in the syringe pump, a PHD 2000 
infusion pump (Harvard Apparatus). The stage and optics were controlled by the 
computer to the left of the stage (not shown). Once the experiment was set to begin, 
the lights were turned off, and a black curtain was pulled around the entire stage to 
conceal the setup from any remaining light. 
  The white-light camera in the imaging setup was used to locate where the  
 Figure 2.1. Imaging setup used in these studies. The anesthetized rat is placed on the 
motorized stage beneath the optics. The infusion pump sits beneath the stage, and 
tubing runs from the syringe containing the nanoparticles to the micromanipulator, 
which holds the infusion needle. 
  
infusion needle entered the brain. The motion of the needle could be tracked under this 
4x objective to the point where the needle was inserted into the brain. It was necessary 
20x objective, which was needed to achieve sufficient spatial resolution to identify 
capillaries and their adjacent perivascular spaces. A better way was developed to 
locate the needle tip inside in the tissue. A 4x objective was still employed, but it was 
used to observe the fluorescence in the field of view, both in the needle and in the 
vasculature. This permitted the identification of the blood vessels and the needle that 
were in the same horizontal plane. By making careful adjustments during insertion, it 
was possible to keep both the needle and the vessels in plane throughout the insertion. 
To do this, the tapered needle shaft was placed directly over the coverslip. The 
micromanipulator was adjusted by one operator while the other operator adjusted the 
camera through software on the computer. The camera operator moved the stage to 
follow the needle tip as the micromanipulator operator moved in plane above the 
coverslip to beyond the edge of the coverslip. The needle tip was then lowered into the 
plane of the coverslip. The 4x objective allowed a wide enough field of view such that 
both the needle tip and the coverslip/vasculature could be seen. From here, the camera 
operator lowered the stage in 100 µm increments, pausing for the micromanipulator 
operator to lower the needle tip into focus, and thus into the imaging plane. Once the 
needle was somewhere between 200  400 µm below the surface to the brain 
(coverslip sat directly on the brain tissue), the needle was inserted into the tissue, 
making sure to avoid any major visible blood vessels. With the needle in the brain, the 
stage was lowered, and the 4x objective was switched out for a 20x objective. The 
coverslip was raised to within 5  10 mm of the objective, where water was added 
between the objective and the coverslip. The imaging plane was close to the plane of 
the needle tip, and slight positional adjustments were necessary to get the needle tip in 
focus. From here, the needle tip was inserted further into the brain, and imaging 
experiments could begin. 
 There are multiple time scales to be aware of during a single loop. The time to 
scan the imaging plane and record the data is 0.317 s for a 512 x 512 pix2 image. The 
distance between each image depth that is being recorded is 2 µm. The time to travel 
to each imaging depth is negligible. In a typical experiment, the total vertical depth 
being imaged is 250 µm, meaning there are 125 images taken in a single direction of 
the loop. This equates to roughly 40 s, or 80 s total recording time for the loop (the up 
and down motion). A single experiment can involve infusions at multiple locations 
within the cortex, with each individual infusion recorded comprised of 4 - 12 loops. It 
is important to remember the manner in which the data was recorded when 
interpreting results. We acquire images w
traverses through the cortex from top to bottom and then bottom to top.  Thus, images 
at any specific plane are not acquired at uniform intervals.  For example, a plane near 
the bottom of the stack is imaged late in the traverse from top to bottom.  However, 
traverses the stack from bottom to top.  The only plane that is imaged at uniform 
intervals is the plane in the center of the stack.  Therefore, the temporal resolution of 
the setup varies depending on the imaging depth. Images near the center of the stack 
will have similar time between them, but images are further apart in time near the 
surface of the brain during a single loop. This time resolution inverts when looking at 
images between loops, as the recorded image at the end of first loop and beginning of 
the second loop occur very close in time. 
The 0.317 s recording time gives a frame capture rate of 3.15 frames/s, which 
equates to about 6 µm moved each second. For an isotropic infusion in the brain, a 
sphere would grow beyond the edge of the viewing plane (about 287 µm) in about 6 s. 
The materials being infused take much longer (order of minutes) to grow beyond the 
field of view. It is therefore possible to record multiple loops for a single infusion and 
observe the movement of the infused materials using this setup. All image data taken 
was recorded using the referenced method for recording loops, or the up and down 
image capture techni
the imaging plane is recorded at a single depth within the cortex, which was primarily 
used in [33] 
 In these imaging experiments, three primary types of infusates were used, 
polystyrene beads, liposomes, and dextrans. The exact sizes and formulations are 
discussed in Chapter 3. The size of the infusate was varied between 20  200 nm for 
the polystyrene beads, and between 50  200 nm for the liposomes. A single size of 3 
kDa dextran was used for select experiments.  
 
2.2.3 Determination of Relevant Parameters 
 
 Volumetric infusion rates for most studies of convection-enhanced delivery in 
rodents vary between 0.1-1 µL/min [17,33,55]. However, these studies involve 
infusion into subcortical regions of the brain such as the caudate, which is often used 
in rodent studies because it is a relatively large homogenous region of gray matter. To 
the maximum allowable depth for 2PEF imaging in tissue is about 1 mm.  The 
thickness of the rodent cortex is only about 2 mm.  To keep the infusate confined to 
the cortex, it was necessary to use a relatively low volumetric infusion rate.  
Therefore, experiments were carried out at an infusion rate of 0.2 µL/min.  
Once the infusion rate was set, the volume of tissue that would have to 
sampled to include the entire infusion volume could be calculated assuming an 
isotopic distribution of infusate and considering the porosity of brain tissue, which is 
about 0.2[56]. This result provided estimates for the magnification that would be 
necessary to capture the infusate volume in the field of view. A magnification between 
1.7 and 2.0 with the 20x objective was used for all the experiments. To accurately 
capture the small, micron scale capillary perivascular movement, a 512 x 512 pix2 
planar resolution was used. Lower resolutions at 256 x 256 pix2, 128 x 128 pix2, and 
64 x 64 pix2 and a higher resolution 1024 x 1024 pix2 were also tested. Sample figures 
for the lower resolutions can be found in Figure 2.2. The selected resolution dictates 
the rate at which the images can be captured, with ~1.6 frames per second being 
captured at 1024 x 1024 pix2, up to ~20 frames per second captured at 64 x 64 pix2. 
The lower resolutions of 256 x 256 pix2, 128 x 128 pix2, and 64 x 64 pix2 sacrificed 
too much image clarity of the smaller vessels. The higher resolution of 1024 x 1024 
pix2 did not reveal anything that could not be seen at 512 x 512 pix2. Therefore, a 
resolution of 512 x 512 pix2 was used to provide a balance between image clarity and  
 Figure 2.2. Sample images illustrating image resolutions. Blood vessels appear green, 
while polystyrene beads appear red. The vasculature and the infusate cloud become 
harder to discern as the resolution decreases from 512 x 512 pix2 (D) to 256 x 256 pix2 
(A), 128 x 128 pix2 (B), and 64 x 64 pix2 (C). Scale bar is 100 µm. 
  
scan rate. This gave an image recording rate of ~3.15 frames per second. Finally, the 
step size in the vertical direction, i.e. into the cortex, was determined by estimating the 
size of the smallest vessels, which was several µm. Therefore, a vertical step size of 2 
µm was chosen, with the intent of capturing all lateral sections of small vessels.  
 
2.2.4 Data Processing 
 
 The raw data from the experiments consisted of stacks of tagged image file 
format (TIFF) images. Each image within a stack is 512 x 512 pix2. The conversion 
between pixel and actual distance depends on the objective and magnification setting. 
During each experiment, the focal plane of the microscope was moved vertically in 
steps over a predetermined travel distance through the cortical tissue by moving the 
microscope stage.  When the focal plane reached the bottom of the travel distance, the 
direction of the stage was reversed, and the focal plane moved upward until it reached 
its initial location.  The direction was reversed, and again the focal plane traveled 
downward through the tissue.  This periodic action continued throughout the 
experiment.  The number of images in a stack depended on the number of vertical 
steps and the total vertical travel distance in the experiment. Each TIFF stack was 
loaded into ImageJ for filtering. A three-dimensional, 1 pix median filter was applied. 
The median filter helps to reduce noise in the image while retaining the edges of 
shapes within the image. The filter looks at the neighboring pixels around each pixel 
in an image, and replaces it with the median value from these neighboring pixel 
intensities. This smoothed out edges of vasculature and infusion clouds, effectively 
removing image hairs and any irregularities brought about by saturation during 
recording. An example of the effect of this filtering on an image is shown in Figure 
2.3. 
 
2.2.5 Extracting Quantitative Features from Images - Automated 
 
 Analysis of the images started by converting them to binary images with a 
specified threshold. Initial development of data processing protocols set the threshold 
manually at a single intensity determined by probing the background pixel intensity 
values. Later, the threshold was set using a script that set the value of the threshold as 
a specified fraction of the mean of the top ten percent of pixel intensity values. To 
determine the top ten percent of the values, all pixel intensity values for a single image 
were concatenated and sorted from smallest to greatest. The mean of the top decile of 
intensity values was calculated. The threshold value was then set to this mean value 
multiplied by an adjustable coefficient. It was determined that a coefficient of 0.05, 
corresponding to 5% of the mean of the top ten percent of the pixel intensity values, 
gave similar values to those that were determined manually. With the threshold level 
set, pixels with intensity values higher than the threshold value were changed to 1, 
with all others set to 0. 
The threshold script was incorporated into to a data analysis script with 
modules that could calculate certain values from the stacks of images. All stacks for a 
single infusion were read into MATLAB one at a time, converted to an array, and 
calculations of infusion cloud volume, surface area, and velocity of the infusion front  
 Figure 2.3. Sample image of infusion cloud. (A) before and (B) after the application 
of the 1 pixel median filter. Green = FITC-dextran; red = red-orange fluorescently 
tagged polystyrene beads.  The image hairs protruding from the cloud in the red 
channel are entirely removed. Scale bar is 100 µm. 
  
were performed in sequence.  
To calculate distribution volume of nanoparticles the number of pixels 
containing nanoparticles, which corresponded to values in the array containing a 1, 
were added together to define the area containing nanoparticles in each image. 
Multiplying this area value for each slice by the thickness of each slice, defined by the 
vertical step distance of the microscope stage, gave the volume of nanoparticles 
contained within each slice of the stack. By adding the volumes of all of these stacks, 
the total volume of distribution of nanoparticles was determined. The area values were 
converted from pix2 to µm2 prior to multiplication by the step size, which was always 
2 µm in our experiments. This is a common volume calculation technique used in 
imaging analysis [37,57].  
 To calculate surface area of the infusate, each voxel, consisting of the 1 x 1 
planar pixel and the 2 µm depth associated with that pixel, and its neighbors are 
examined. For each adjacent voxel with a value of 0 (indicating that there are no 
nanoparticles in that adjacent voxel), the surface area is increased by 1, up to a 
maximum value of 6 (a voxel described here is a rectangular prism, with 6 faces), 
indicating a voxel containing nanoparticles is free from any adjacent nanoparticle-
containing voxel. The area is summed, and converted to µm to give a total surface area 
for each image. The total surface area for the volume sample is found by adding up all 
the surface area values for the sampling of the cloud (which is a one direction sample 
of the cloud). 
 To calculate the parenchymal velocity, referred to as the cloud front of the 
infusion, code was written to sample the extent of penetration of the nanoparticles in 
several directions from the point of infusion. The velocity of the moving particles 
could only be distinguished at the edge of the cloud. A total of 26 directions were 
sampled, corresponding to 8 compass directions around the needle outlet in plane, the 
8 compass directions around a pixel directly above and directly below the needle 
outlet, and the vertical directions from the needle outlet. By tracking the pixels along 
the edge of the cloud front in these directions, the velocities of the nanoparticles 
traveling in each of these directions could be monitored over the whole infusion, 
giving insights into nanoparticle transport for each of the infusions.  
 Code developed for the data analysis portion of this work can be found in the 
appendix. 
 
2.2.6 Extracting Quantitative Features from Images  Manual 
 
 To calculate the volume of the cloud, the radius of the cloud in the plane of the 
needle outlet was measured in the direction of the needle and in directions normal to 
it. These radii were averaged, giving a mean radius. Infusions resemble a sphere with 
protrusions corresponding to perivascular routes. The radius was used to calculate the 
volume of the spherical portion of the cloud, thus giving an estimate for the 
parenchymal distribution volume. The values were calculated for each time the 
imaging plane passed through the cloud, giving increasing values with each pass.  
 To calculate the volume of the perivascular spaces manually, an ImageJ plugin 
location alongside a vessel, and the plugin was used to measure the length of the 
observed particles in the perivascular space. The width of associated vessels and the 
perivascular width was also measured, which allowed for calculation of both the 
perivascular volumes and velocities along these routes. 
 Chapter 3 bases all the data on manual measurements. Developing these 
algorithms and protocols for discerning these quantitative features was a large part of 




2.3.1 Sample Infusion Data  2D Output TIFF Stacks 
 
 Each stack of TIFF images contains the fluorescence emission captured during 
a single cycle through the cortex, which corresponds to one upward movement of the 
stage followed by the downward movement. This gives an image stack that appears to 
be capturing images while moving down into the cortex, and subsequently back up 
and out of the cortex. A representative example of images demonstrating parenchymal 
and perivascular transport of nanoparticles during a downward traverse of the imaging 
plane in the cortex is shown in Figure 2.4. Figure 2.4A is at the top of the image 
stack, corresponding to a depth of 0 m. Figure 2.4B-D display images at 25 m 
distance increments into the brain, with B at 25 m, C at 50 m, and D at 75 m into 
the cortex (where the infusion needle can also be seen). The presence of perivascular 
routes surrounding small blood vessels can be seen in Figure 2.4A-B. Again, the 
presence of perivascular spaces is discerned by their annular shape encompassing 
vessels, shown in green. The nanoparticles colored red, in this case, 200 nm 
polystyrene beads, can be seen in the PVS. The imaging records the fluorescence 
channel. In ImageJ, the two channels can be separated or combined into a composite 
(as shown in Figure 2.4) of the two images at each depth. This technique is common 
for visualizing the fluorescence data [27,33], and most images shown in this work are 
 
 
2.3.2 3D Rendering of 2D TIFF Stacks 
 
 The imaging technique used here allows for 3D reconstruction of the infusion 
cloud over a ~30 s portion of an infusion, as this is the required time for the imaging to 
capture the infusate distribution volume once, in either a downward or upward pass 
through the infusate cloud. An example of a 3D reconstruction is shown in Figure 2.5. 
Figure 2.5A shows a view of the 3D reconstruction looking down on the cloud from 
above. Figure 2.5B shows the same view of the 3D reconstruction angled to show the 
depth of the reconstruction, which cannot be discerned from a purely top-down view. 
From this 3D rendering of the data, the perivascular paths and overall cloud 
morphology are easily visible, and act as a guide for further, more detailed inspection 
in 2D images. The 3D renderings offer a unique way of displaying relevant spatial 
information about the distributions of nanoparticles without needing to show multiple 
frames during an infusion. 
  
 Figure 2.4. Sequence of images from a single loop during a 200 nm polystyrene bead 
nanoparticle infusion (towards the middle of the infusion, after infusing for about 8 
minutes). Both parenchymal and perivascular transport can be seen in the sequence. 
Green = FITC-dextran; red = red-orange fluorescently tagged polystyrene beads. (A) 
Image near surface of the brain. Depth = 0 µm, time into infusion = 411 s. (B) Depth = 
25 µm, time into infusion = 419 s. (C) Depth = 50 µm, time into infusion = 427 s. (D) 
depth = 75 µm, time into infusion = 435 s. Scale bar is 100 µm. Arrows indicate 
perivascular routes, which are identified by their adjacent location to vasculature 
(green due to FITC).  
 Figure 2.5. 3D reconstruction of one stack of images from a 200 nm polystyrene bead 
infusion. The reconstruction shows the location of particles during the interval from 
248 s to 287 s of the infusion. (A) Top-down view of the 3D reconstruction. (B) 
Rotated view of the 3D reconstruction, which sometimes allows for better recognition 
of PVS transport. Scale bar is 100 µm. 
  
2.3.3 Time-Lapse Images and PVS Identification 
 
 Identification of relevant perivascular spaces involves a combination of 
viewing entire infusions as 2D images through time and 3D reconstruction. To 
estimate the spatia  
m through known 
conversion factors provided by the imaging software. An example from this 
perivascular identification process is shown in Figure 2.6. Figure 2.6A-B show 
examples from steps in the 2D and 3D process of finding local PVS. In Figure 2.6A, 
the local PVS are spotted using the 2D stack of images, and confirmed in location in 
Figure 2.6B. In Figure 2.6C
load the red channel only, isolating the nanoparticles in the image for the script to 
analyze. A location is entered by the user to define the PVS entrance along the edge of 
the cloud, and locations of points within the PVS are added by the user as the script 
interpolates the path between the given points. Figure 2.6D shows the output from the 
script, highlighting in magenta the identified PVS routes. All the PVS routes are saved 
with an identifier for later reference. This determination of PVS allows for comparison 
to comparable parenchymal movement, both in time and in position from the needle 
tip. 
 
2.3.4 Different Magnifications 
 
 Most of the data collected over the course of this work involves the use of a  
 Figure 2.6. General process for identifying and measuring length of PVS. Green = 
FITC-dextran; red = red-orange fluorescently tagged polystyrene beads. (A) Sample 
imaging plane from 2D image stack used to locate PVS. (B) Sample 3D reconstruction 
used to identify location of PVS. (C) 
requires loading of a single channel, so the particles are separated from the 
vasculature. Only the infusion cloud is shown, and is used with the script to trace the 
PVS. (D) The traced PVS paths identified by the script. The user selects a location, 
and multiple points along the PVS, and the script interpolates the path of the PVS 
along those points. Magenta lines indicate traced paths. Image of traced paths is 
catalogued for later reference. Scale bar is 100 µm. 
  
20X objective, giving much greater spatial resolution at the expense of field of view. 
For examining the wider view of where nanoparticles travel during the infusion, a 4X 
objective is used. Sample images taken using this lower magnification objective are 
shown in Figure 2.7. While most perivascular nanoparticles are not discernable at this 
lower magnification, the parenchymal movement of particles relative to larger 
vasculature and structures can be observed.  
 
2.3.5 Identification of Non-PVS Fluid Routes 
 
 Evidence of fluid pathways that are larger than the mean ECS pore size 
estimated in [39] is observed five infusions. These pathways are observed for the 
largest size of particles, 200 nm. An example of this observation is shown in Figure 
2.8. The arrows indicate the direction of flow for this observation. This phenomenon 
would not be observable without collecting data in the oscillatory manner discussed in 
this section, as other imaging techniques would not have the resolution to observe the 
micron-scale movement of the nanoparticle infusate through these fluid pathways. A 
fixed imaging depth experiment would likely miss the progression of the nanoparticles 
through these fluid routes unless a route happened to lie in the fixed imaging plane, 
which is unlikely. The pathways observed protruded from the edge of the infusion 
cloud through the parenchyma to a perivascular space. This does not mean that these 
paths are not present for other particle sizes, but rather that the 200 nm move slowly 
enough that the movement of the nanoparticles into these pathways can be observed 
by the imaging.  
 Figure 2.7. Sample image of different magnifications. Green = FITC-dextran; red = 
red-orange fluorescently tagged polystyrene beads. On the left, the 4x objective gives 
objective can view the entire open craniotomy, but lacks fine resolution. The fine 
resolution provided by the 20x objective allows for investigation of micron-scale 
movements of the infusate. Scale bar is 100 µm. 
  
 Figure 2.8. Sample of pathway leading from edge of infusion cloud to viable 
perivascular space. Direction of flow and path taken is indicated by the arrows. The 
image on the left is near the point of infusion, ~250 µm below the surface of the brain. 
The image on the right is the surface of the brain. The infusate (200 nm liposomes in 
follows a series of interconnected vessels up to the surface, as demonstrated by the 




 We developed an experimental setup for viewing CED-like infusions with 
unparalleled resolution. MRI has been used to view infusions at a larger scale 
[37,38,58], and fluorescence imaging has been used to view microvasculature and 
other micron-scale behavior [33,43,50,51]. The combination of a ~2.5 µm3 voxel size 
with a volume sample rate of ~30 s allows for detailed views of the movement of 
infused particles into the brain environment. Previous work in our lab had shown 
particles moving through the parenchyma and the PVS at vastly different speeds by 
watching a plane above the point of infusion. Here, a system has been developed to 
track the evolution of the three-dimensional nanoparticle cloud in real time 
continuously throughout the entire infusion. In previous experiments, the shape, as 
well as instantaneous velocity and volume of the developing cloud was not obtained. 
This method can track the entrance of infused materials into the PVS, and follow them 
for short amounts of time before they exit the field of view.  
 Previous research lacks detailed resolution [59,60]. A more detailed 
understanding of the motion of therapeutic compounds injected into the brain is 
needed to predict whether a CED-based treatment could prove effective. The lack of 
understanding of infusate location during a CED infusion could be a contributing 
factor in diminishing the efficacy of new treatments in clinically relevant situations 
[61].  
 The presence of larger pore sizes for the ECS have been reported in [42,62]. 
The fluid pathway shown in Figure 2.8 could be something as simple as a larger pore 
near the site of infusion. The nature of the nanoparticle movement, in that these 
pathways appear to lead into PVS, indicates that they may play a role in a larger fluid 
drainage system. Furthermore, they may be present for the other particle sizes and 
types, but could not be observed due to cloud overtaking that section of the 
parenchyma while other parts of the infusion were imaged. 
 Most of the experiments done using this experimental setup involve only two 
channels; a red channel for the nanoparticles and a green channel for the vasculature. 
The system has since been upgraded to four channels, which allows for viewing of 
multiple infusates or illumination of other local structures. Astrocytic endfeet play an 
important role in regulation of the fluid moving in the PVS [43]. If the astrocytes 
could be visualized using a separate color, multiple infusates could be observed 
This could lead to further understanding of the role the astrocytes play in the event of 
therapeutics being introduced into the local environment during a CED-like infusion. 
 There are drawbacks to this system. The largest is the lack of imaging depth, in 
that we can only observe up to ~500 µm into the cortex. This limits current 
experiments, at least in their current state, to rodent experimentation. This drawback 
will be somewhat mitigated by the advent of higher-photon imaging modalities, which 
will allow for greater depth imaging [35]. Furthermore, the field of view in our 
experiments is always between 500 x 500 to 700 x 700 µm2, which is quite limited, 
especially when trying to extrapolate results to a clinically relevant scale. 
 It is important to understand that the development of this system and 
experiments performed with this system are for elucidating the mechanisms that 
underlie the movement of therapeutics during a CED-like infusion. We can only 
predict based on evidence where materials will go. By varying particle size and type, 
we can make general statements about the relative rates of transport within the rodent 
brain environment. With appropriate scaling and future investigation into transport in 
higher order animals and humans, it is possible that these findings will directly 
extrapolate, although this is purely speculative and similar investigation in higher 
order animals and human trials would be necessary to confirm or deny this. Further 
testing for comparison will be needed to determine scale up, and future experiments 
will be needed to determine why materials move to the places that they do at certain 
times. It is possible that the bulk fluid movement systems proposed by Iliff et al. [43] 
carry over to CED-conditions, in that the observed motion during a CED-infusion 
could be sum of the infusion motion and the bulk fluid movement from arterioles to 
venuoles in the parenchyma. Speculation like this could be further investigated by 
varying the influence of the bulk fluid movement system, perhaps by varying the 
heartrate of the animal. In future work, if it were possible to identify available PVS 
prior to CED-infusion, the infusion cloud morphology could be predicted in a more 
precise manner, and infusion characteristics such as infusion location, flow rate, and 




Imaging of infusates has evolved in complexity in recent years. From post-
mortem brain slice analysis to MRI imaging of various tracers, visualization of 
transport in the brain has added to the understanding of the underlying mechanisms 
that govern therapeutic movement in the brain. With the development of our system, 
we are able to see infusates move with greater spatial and temporal resolution than 
what has been accomplished previously. With micron-scale spatial resolution, we are 
able to see the infusate enter perivascular pathways, and can discern its location as it 
moves about the local area. The development of this system allowed for the 
experiments detailed in Chapter 3 to occur, in which numerous quantitative properties 
of the infusion are calculated from our imaging method. These findings allow for 
greater understanding of therapeutic transport in the rat cortex, which can be 
extrapolated to higher order animals, and potentially humans.  
CHAPTER 3 
 
PROBING PERIVASCULAR TRANSPORT DYNAMICS USING IN VIVO, HIGH 




Free drugs introduced into the bloodstream are not effective for treating many 
central nervous system (CNS) disorders. They are prone to poor solubility, limited 
biodistribution, unfavorable pharmacokinetics, and rapid breakdown [63] when 
treating systemic diseases. The brain is guarded by the blood-brain barrier, a series of 
tight junctions formed by endothelial cells that line brain capillaries, which limits the 
compounds that can enter the brain. Small lipophilic molecules (<400 Da) and 
facilitated materials can cross the barrier, but most drugs introduced into the 
bloodstream do not readily cross. 
Convection-enhanced delivery (CED) is a local drug delivery method that 
circumvents the blood-brain barrier by delivering therapeutic compounds directly into 
the brain interstitium through a catheter or needle that is implanted into the brain.  
CED is used in clinical trials with humans and in experiments involving animals to 
deliver an array of therapeutics to treat CNS disorders.  One of the most innovative 
CED strategies involves delivering therapeutic-containing nanoparticles deep inside 
the brain parenchyma where the nanoparticles can release the therapeutic over long 
times following CED delivery.  Encapsulating therapeutic compounds inside particles 
protects the therapeutic against clearance during transport of the nanoparticles through 
the brain. Polymeric nanoparticles that have been tested in CED studies include 
particles composed of polylactide-co-glycolic acid (PLGA) [40,41,64,65], polystyrene 
[41], polycaprolactone (PCL) [64] and polylactide-PCL [22]. Liposomes [66 69], 
lipid based carriers [14], and iron oxide nanoparticles [70], have also been used in 
CED experiments.  
The size of the nanoparticles has proved to significantly affect their transport 
through tissue with CED.  Larger particles can carry a greater therapeutic payload, but 
transport of larger particles may be diminished due to hindrance that increases with 
size. Thus, a range of particle sizes has been investigated. Nance et al. analyzed the 
movements PEG and carboxylic acid modified polystyrene nanoparticles of 40, 100 
and 200 nm to discern the effect of size and surface coatings on the transport of 
infused materials in cortical slices [41]. Arshad et al. developed therapeutically 
effective carboplatin PLGA nanoparticles with an average diameter 175 ± 40.75 nm 
for the treatment of gliomas via CED [71]. Bernal et al. showed prolonged survival of 
animals with intracranial xenografts after infusion of a mixture of 30 to 75 nm 
temozolomide containing iron oxide particles [72]. Krauze et al. used liposomes of 
average diameter 85.1 ± 37.5 nm and 79.0 ± 34.3 nm to investigate perivascular 
transport throughout CNS arteries upon infusion into the putamen of monkeys [34]. 
While the development of various nanoparticles has increased since CED was 
first developed, the distribution of nanoparticles after injection into the brain remains 
difficult to predict, especially since it may depend on the local anatomy. Gray and 
white matter have different diffusional resistances [73,74] and hydraulic conductivities 
[75], and the presence of highly-conductive fluid pathways further complicates 
accurate prediction of infusate trajectory in vivo[33]. Numerical simulations to predict 
fluid flow in vivo have been developed and often are used in clinical trials of CED 
[21,22,76 78], but they include only the conspicuous features of the local anatomy, if 
they include any at all. Without extensive knowledge of local anatomy and variations 
in tissue properties, predicting the fate of therapeutics in the brain is challenging.   
The inability to disperse infused material throughout the brain may be 
responsible for the limited improvement of patient outcome at the clinical level with 
CED. The PRECISE clinical trial used CED to deliver cintredekin besudotox (CB), a 
recombinant chimeric cytotoxin that targets and kills tumor cells that express a 
specific receptor found on gliomas.  Results from the clinical trial showed no 
significant advantage in survival outcome over Gliadel wafer treatments [79]. Several 
potential reasons are offered to explain the failure of CED to improve patient 
outcomes, including variations in catheter placement, infusion rate, and total infusion 
volume. However, the largest factor limiting the effectiveness of CED treatment is the 
uncertainty of achieving sufficient concentrations of the therapeutic at distant target 
sites.   
The goal of this work is to use two-photon fluorescence microscopy to 
examine the motion of nanoparticles infused in the cortex of rodents to better 
understand how local anatomy and vasculature influence the distribution of infused 
material.  The imaging system described in Chapter 2 will be used to characterize the 
transport of various nanoparticles injected during a CED-like infusion. The studies 
will examine the role of size on transport of rigid polymeric particles and deformable 
liposomes. By examining the locations of nanoparticles infused into the cortex at 
various times during an infusion, we aim to determine various quantitative features of 
the infusion, such as penetration distance of the particles, volume of distribution (VD) 
vs. volume of infusion (VI), and velocities of particles in the parenchyma and in the 
perivascular spaces. With this information, a greater understanding of where 
nanoparticles go during a CED infusion into the cortex can be attained. 
 
3.2 Materials and Methods 
 
3.2.1  Nanoparticle Preparation 
 
Carboxylate-modified polystyrene fluorescent nanoparticle solutions (20, 40, 
100 and 200 nm FluoSpheres, Life Technologies) were sonicated for 15 min. The 
nanoparticles were then diluted to 0.1 wt% solids in a solution of 1 wt% bovine serum 
albumin (BSA, Sigma-Aldrich, St. Louis, MO) in phosphate buffered saline. 
Nanoparticle solutions were mixed on laboratory rocker at low speed for 4 h. BSA 
conjugation to carboxylate-modified surface reduces surface charge of polystyrene 
nanoparticles, decreasing non-specific binding of the nanoparticles upon infusion into 
rodent brain. 
Fuchsia-colored suspensions of 50, 100, and 200 nm liposomes were procured 
from Avanti Polar Lipids, Inc. These liposomes were formulated in a molar ratio of 
55:44:1 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC): cholesterol: Texas Red 
1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine (DHPE). The formulation 
involved extrusion through appropriate filters to form liposomes of the desired size. 
The liposomes were suspended in buffer solution containing 10 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES buffer), pH 7.4, 150 mM 
NaCl, and 1 mM MgCl2. 
Size and surface charge were determined for the liposomes and for the 
polystyrene beads both before and after BSA incubation of the polystyrene beads 
(Zetasizer Nano, Malvern Instruments Ltd., UK). The measured sizes and zeta 
potentials of the particles are contained in Table 3.1.  
Dynamic light scattering (DLS) characterization techniques are sensitive to the 
presence of large particles in the solution. Large particles can change the average 
diameter measured by the Zetasizer, which may explain the larger than anticipated 
average particle diameter. The hydrodynamic diameter of BSA is ~7 nm [80], and the 
presence of a BSA molecule surrounding the surface of the polystyrene nanoparticle 
helps explain the increase in the diameter of the particles when conjugated with BSA. 
BSA conjugation clearly reduces the zeta potential of the particles, thus helping to 
reduce non-specific binding once infused into the brain parenchyma during these 
experiments. As for the liposomes, the polydispersity index (PDI) indicates that there  
is a large range of particle sizes in the suspension, with the average influenced by the 
presence of larger particles in the suspension. Investigation into Zetasizer data 
indicated that for the 50 nm particles, over half were in the range of 50-100 nm.  
Cascade Blue-dextran was used to track fluid motion independent of the 
-
dextran was prepared by mixing 1 wt% Cascade Blue dextran in phosphate buffered  
  
  
saline solution with 0.1 wt% 200 nm nanoparticle solution in a 1:4 ratio. 
 
3.2.2  Infusion Setup Preparation 
 
The craniotomy protocol described in Ch.2 was used here.  After the 
craniotomy, the subject was transferred to the imaging setup. The animal was placed 
on a motorized stage beneath the two-photon excitation fluorescence (2PEF) 
microscope objective. A 4X objective (Zeiss) was used to examine the craniotomy 
during insertion of the CED needle. Using a micromanipulator, a fixed rod that held a 
needle (prepared using P-97 Flaming/Brown Micropipette Puller, Sutter Instrument) of 
outer diameter ~10 µm was brought into the field of view above the coverslip. The 
needle was then retracted, lowered, and then inserted into the brain in a direction 
parallel to the surface of the brain at a depth below the brain surface between 100 and 
400 µm. The pipette could be seen under 2PEF due to the presence of nanoparticle 
solution, which was primed to the distal end of the needle. The vasculature and 
nanoparticles could be identified in separate channels on the imaging computer, as the 
blood vessels were labeled with fluorescein isothiocyanate (FITC)-dextran from a 1 
mL tail vein injection, and the nanoparticles were labeled with a red (580 
excitation/605 emission)-fluorescent molecule. Once the needle was in the tissue, the 
4X objective was replaced by a 20X, water-immersed objective (Zeiss or Olympus). 
 
3.2.3  Imaging Experiments 
 
2PEF images were taken on a custom-built two-channel microscope using 100 
fs duration pulses from a 76 MHz repetition rate Ti:sapphire laser system (Mira-HP, 
Coherent, Santa Clara, CA) pumped by a continuous wave laser (Verdi-V18, 
Coherent, Santa Clara, CA). Excitation wavelength was set to 800 nm, which excited 
both the FITC and the red nanoparticles. Fluorescence collection was achieved using a 
610-nm and 530-nm bandpass filter. ScanImage (r3.8.1, Janelia Farm, USA) was used 
for image acquisition. High magnification images were captured with a 1.0 NA, 20x 
water immersion objective (Zeiss, Thornwood, NY).  
Infusions were made at a flow rate of 0.2 µL/min using a PHD-2000 constant 
flow infusion pump (Harvard Apparatus). During the infusion, the motorized stage 
was used to move the animal and micromanipulator vertically under the objective. The 
stage was programmed to move up and down periodically.  The imaging plane was 
fixed in space, but the relative motion of the tissue allowed the imaging plane to scan 
through the cortical tissue periodically.  Thus, the vasculature and the infusion cloud 
were sampled in each plane at discrete times. The period of the stage motion ranged 
between 60 and 90 s. depending on the total vertical depth being imaged.  The distance 
traveled by the stage during each half-p
512 x 512 pixel images were captured at a frame rate of 3.15 frame 
per second. This resolution and frame rate were previously determined to be sufficient 
for viewing transport with spatial and temporal resolution that could reveal details of 
the infusate motion.  
Multiple infusions were performed with a single animal. The edge of each 
infusion cloud could be seen, meaning each subsequent infusion needed to be done 
where the field of view would not pick up any residual fluorescence from a previous 
infusion. The needle was withdrawn and reinserted to avoid any overlapping regions 
from a previous infusion. At the end of the experiment, pentobarbital was 
administered via intraperitoneal injection to induce euthanasia. 
 
3.2.4  Image Analysis 
 
2PEF imaging files were exported as multi-image tagged image file format 
(TIFF) stacks for analysis in ImageJ (National Institutes of Health, Bethesda, MD) and 
MATLAB (Mathworks, Natick, MA). Image stacks were individually loaded into 
ImageJ. A 1-pixel 3D median filter was used to remove noise from the images. Then, 
the two channels were combined into a composite image for each depth in the brain. 
Brightness and contrast were adjusted for viewing and data analysis. Perivascular 
routes and parenchymal cloud growth could be assessed using these image stacks, with 
perivascular routes identified as areas where nanoparticles were adjacent to blood 
vessels. Filtered image stacks were individually loaded into MATLAB. A threshold 
was calculated based on image histograms to remove background noise. Then, various 
quantitative properties of the infusions were measured, including average radius of the 




3.3.1  Nanoparticle Experiments 
  To gain a fundamental understanding of the movement of nanoparticles 
injected during a CED-like infusion, we continuously imaged nanoparticles as they 
were infused.  This allowed us to evaluate numerous aspects of the infusion with 
unparalleled temporal (~30 s per recording of infusate volume) and spatial (~2.5 m3 
voxel size) resolution. We found that nanoparticles of all sizes can travel along 
perivascular routes, and the presence of these perivascular routes influences the 
morphology of the infusion cloud. Furthermore, velocities could be estimated for 
perivascular pathways, which allows for direct comparison to parenchymal transport. 
 The sampling of the volume occupied by nanoparticles during the experiment 
allows for reconstruction of the cloud in ImageJ. A typical MRI reconstruction would 
have about 20% of the available volume samples, with significantly reduced spatial 
resolution. The 2PEF technique used here can accurately track the progression of the 
growth of the cloud, which is necessary for understanding nanoparticle dynamics at 
this scale. 
 
3.3.2  Cloud Morphology 
 
 
diameter. For the 20 nm nanoparticles and for liposomes of all sizes in this 
experiment, the infusion cloud closely resembled a sphere. However, for nanoparticles 
of larger sizes (40, 100, and 200 nm), the growth of the infusion cloud was strongly 
influenced by perivascular routes. The clouds formed by the larger beads have a 
spherical portion indicative of isotropic growth, but they also have protrusions from 
the spherical boundary that lead to perivascular spaces.  
 Figure 3.1 depicts 3D reconstructions of infusion clouds for liposomes (50, 
100, and 200 nm) and for nanoparticles (20, 40, 100, and 200 nm).  Each row contains 
images of the infusion cloud at short, medium, and long times throughout the infusion.  
 The perivascular routes for liposome transport are readily visible in most of the 
frames for the liposomes.  For example, all frames of Figure 3.1A, which pertain to 50 
nm liposomes, show clearly defined perivascular routes extending beyond the edges of 
the infusion cloud. The growth rate of the cloud, i.e. the speed of the edge of the 
cloud, is comparable to the speed of liposomes in perivascular spaces for the short and 
middle times. However, for longer times, the rate of penetration of particles along 
perivascular routes is considerably faster than the growth of the cloud boundary.  
Thus, the extensions of fluorescence beyond the edge of the cloud grow in time 
relative to the edge of the cloud. 
In Figures 3.1B-C, the 100 and 200 nm liposome clouds have similar overall 
morphologies, but the growth rate of the cloud for 200 nm liposomes is slightly less 
than that for the smaller 100 nm liposomes.  In any event, it is clear that relatively 
large liposomes, i.e. much larger than the estimated average pore size (38-64 nm [39]) 
of the extracellular space (ECS), are able to move through the interstitial space during 
a pressure-driven CED-like infusion.  However, liposomes of all sizes in the 




 Images for rigid nanoparticles in Figures 3.1D-G show that the growth rate of 
in the infusion cloud decreases with increasing particle size. The slowest growth rate 
is observed for the 200 nm polystyrene beads (Figure 3.1G).  In this case, perivascular 
routes are clearly visible, especially near the infusion needle. 
The data show that nanoparticles with sizes comparable to or greater than the 
estimated pore size of the interstitium can move through the interstitium, albeit at rates 
that depend on particle size. It is reasonable to expect that the motion of the 
nanoparticles through the interstitium is hindered in these cases.  If resistance to fluid 
motion in the perivascular spaces outside blood vessels is less that than in the 
interstitial space, fluid flow could be preferentially diverted toward the perivascular 
spaces. This should be reflected in the trajectories of the suspended nanoparticles, too.   
However, in some instances protrusions from the spherical core of the cloud 
were not always linked to readily identifiable perivascular spaces. In a few cases, 
anisotropy in the infusion cloud was not correlated with the presence of local blood 
vessels.  This suggests the presence of higher-conductivity pathways that are not 
correlated with perivascular spaces. Figure 3.2 depicts an example of this behavior. In 
Figure 3.2, a sequence of images of a loop for a 200 nm polystyrene bead infusion is 
shown. In column A, a perivascular route is shown in 2 µm increments, from near the 
top of the PVS at the top of the image sequence, and down through the PVS and 
associated vessel through the image sequence. In column B, there is an example of 
nanoparticle movement in a narrow channel without the presence of an associated 
blood vessel. The image sequence shows the surface of the brain in the first image, 2 





nanoparticles to the cloud near the needle in the final image. The presence of this 
channel could be due to the location of larger ECS pores in the area, which were 
proposed and studied by Nance et al. [41].  
 
3.3.3 Volume of Distribution 
 
 The volume of distribution (VD) is the volume of tissue that contains 
nanoparticles.  The volume of distribution is small than the infused volume (VI) 
because the motion of nanoparticles is hindered, and they do move at the same speed 
as that of the fluid.  The volume of distribution can be calculated based on the images 
obtained from the 2PEF.  In this case, the total volume of distribution consists of two 
parts: the contribution from the spherical core for each infusion, which can be 
obtained by measuring the radius of the cloud near the needle outlet, and the 
perivascular routes, which can be measured using the simple neurite tracer plugin from 
ImageJ. All measurements are initially taken in pixels and then converted to µm3 or 
µL. For the spherical portion of the infusion cloud, this calculation is trivial because 
the radius lies in the focal plane and the conversion from pixel to length is known. The 
conversion factor in the focal plan differs from the conversion factor in the vertical 
direction, as the voxel is a rectangular prism with a longer vertical length than in-plane 
length. With the correct conversion factors, we can find the true perivascular length in 
µm, which along with the measured PVS width and vessel radius can be used to 
calculate the perivascular volume for each route, using the equation: 
 
where L is the measured length of the PVS route, r is the measured radius of the blood 
vessel, and w is the measured width of the perivascular annulus. For example, for an 
infusion of  200 nm polystyrene beads, the measured length of a PVS was found to be 
3, or 1.34 x 10-5  
 Figure 3.3A shows the volume of distribution VD as a function of volume of 
infusion VI for each particle size. The left side of Figure 3.3A pertains to liposomes; 
the right side of the panel pertains to rigid polystyrene nanoparticles. Figure 3.3B 
shows VD as a function of VI for 200 nm polystyrene beads. The slope of each linear 
fit of the data is the VD/VI ratio; the average of the slopes for a particular size and type 
is displayed in Figure 3.3A. This gives evidence of the assertion that the ECS pore 
size plays a role in hindering the movement of particles as the average pore is 
approached and exceeded, as the 50 nm liposomes showed significantly higher VD/VI 
than the other two liposome sizes tested. The 20 and 40 nm polystyrene beads showed 
a similar average VD/VI, but decreased for 100 nm, and further decreased for 200 nm. 
The values of VD/VI for liposomes are between three and eight times greater than the 
values of VD/VI for polystyrene beads of similar size. 
 
3.3.4 Parenchymal Transport 
 
 Upon entering the brain tissue, nanoparticles are hindered as they move 
through the ECS. All of the nanoparticles show sharp declines in initial velocity with 





shows examples of the measured cloud radii as a function of infusion time, the 
velocity of the cloud front as a function of infusion time, and the aggregate (all of the 
infusions on a single plot) radius/velocity data for all infusions of each particle type. 
The top image in Figure 3.4A shows the cloud radius for a single infusion of 200 nm 
polystyrene beads. The data points are the measured radii at various times in the 
infusion, which are obtained by measuring the radial extent of the cloud in four 
directions about the needle tip. The fit through the data points is of the form: 
 
where Q is the volumetric flow rate (0.2 µL/min),  is the porosity of brain tissue 
(0.2), t is time and  is a coefficient representing the ratio between the measured 
radius of the nanoparticle cloud and the radius of an equivalent sphere having the 
same volume as VD. Thus, the value of  is a measure of deviation from sphericity of 
the infusion cloud.  However, since the nanoparticles move through the tissue with a 
speed that is smaller than that of the fluid, the value of  also reflects the degree of 
balance that equates the volume of distribution, adjusted by the tissue porosity, to the 
volume infused.   
 For smaller, unhindered particles, the infusion cloud could reflect an isotropic 
expansion of the nanoparticles, which would correspond to a value of unity for the 
For larger nanoparticles, 
nanoparticles approaches the size of the pore that the nanoparticles must negotiate to 
move through the porous medium. Steric hindrance and non-specific binding of the 
nanoparticles to cells or to constituents of the extracellular matrix can also contribute 
to a lower value of . In practice, the prefactor shown in the equation can be found 
simply by fitting the data to the suggested scaling of t1/3. The values for the prefactor 
from each fit and the measured values of  can be found in Table 3.2. Both aggregate 
data (all the infusions plotted with a single curve fit through them) and individual data 
averages (each infusion plotted separately, with individual curve fits) show a decrease 
in alpha with increasing particle size. Aggregate values found are similar to those 
found from averaging the individual curve fits.  
 The fastest traveling particles in this experiment were the 50 nm liposomes.  
The extent of their travel was 16% of that of an isotropically expanding, unhindered 
sphere over the course of the infusion. The slowest traveling particles, the 200 nm 
polystyrene beads, reached a distance of about 9% of an isotropically expanding, 
unhindered sphere over the course of the infusion. The liposomes had higher values 
which could indicate that the flexibility of 
the liposomes enhanced their motion into the tissue. 
 Figure 3.4B shows the cloudfront velocities for a single infusion of 200 nm 
polystyrene beads. The velocity is calculated by dividing the change in radius by the 







 Figure 3.4C-I shows the aggregate data with curve fit for the measured cloud 
radius as a function of time for the infusates, and Figure 3.4J-P shows the aggregate 
data with curve fit for the cloud front velocity. For a given time, the 20 and 40 nm 
beads can reach larger distances in the parenchyma than the 100 and 200 nm sizes. 
The smaller beads move with less hindrance than the larger beads: they move fast 
enough that they reach the edge of the viewing range in relatively short times, 
compared with the larger particles. The liposomes show similar behavior to the beads 
with respect to the radial behavior across particle diameter.  
 In every case, the velocities of the particles decreased as t(-2/3) . In general, after 
the first 30 to 60 s of the infusion, the particles were moving at less than 1 µm/s 
speeds along the edge of the cloud. This continued to decrease with increasing 
infusion time. The smaller particles maintained a higher cloud front velocity for longer 
times than the larger particles.  
 The prefactors from each fit can be used to plot predictive curves for where the 
radius of the cloud will be for each particle type. In a similar manner, the predicted 
cloud front velocities can be plotted vs. time. These plots allow for direct comparison 
of predicted cloud behavior, and can be found in Figure 3.5. The aggregate prefactors 
are used for the plots shown. From Figure 3.5, the greater radius and cloudfront 






Figure 3.5. Power-law predictions of radius of cloud vs. time and velocity of 
cloudfront vs. time. Aggregate prefactors are used to generate the curves. Smaller 
particles maintain a higher velocity as the cloud moves outward from the point of 
infusion, while the velocity of larger particles decreases more rapidly with distance.  
Liposomes maintain a higher velocity than polystyrene beads of comparable size. 
  
3.3.5 Perivascular Transport 
 
 Once particles reach a PVS, they follow the contours of the PVS, and penetrate 
the tissue beyond the cloud front.  This change in transport modality leads to the 
anisotropy in the cloud shape, as shown in Figure 3.1.  
 Figures 3.6 A-B display histograms of vessel diameter and PVS width for 
every perivascular route containing nanoparticles over the course of the entire 
infusion. More than 90% of vessels in the imaged volume do not show evidence of 
nanoparticles in a PVS associated with the vessels.  Some PVS were accessed readily 
during the first few loops of the infusion, while others required longer times for the 
nanoparticles to enter a perivascular route. Within the network of capillaries, 
arterioles/venules, and arteries/veins, between one and six vessels had nanoparticles 
located in a space identified as a PVS.  
 Figure 3.6A shows most vessels with nanoparticles in their PVS had vessel 
diameters less than 20 µm. This result could depend on the infusion point, which was 
100 to 300 µm below the cortical surface. The nearest available PVS would likely be 
along a capillary. Nanoparticles did not appear to move directly toward a larger vessel 
if there were available PVS along a local capillary. For infusates to enter larger PVS, 
there needed to be larger vessels in the immediate vicinity of the infusion cloud. 
 Figure 3.6B shows most PVS widths are between 1 and 10 µm. Thus, the 
largest particles used in this experiment were considerably smaller than the smallest 
measured PVS width.   




averaged over all observations for a given particle type and size.   The liposomes, to 
the left of the vertical line, show a slight dependence on size, insofar as the 50 nm 
liposomes moved, on the average, about 20% faster than the larger liposomes.  The 
difference in average speed between 100 nm and 200 nm liposomes was small. The 
average measured speeds of the rigid polystyrene nanoparticles were practically 
independent of size from 20 to 200 nm. Furthermore, the average speed of all rigid 
nanoparticles, regardless of size, was comparable to the speeds of the 100 and 200 nm 
liposomes.   
 Figure 3.6C-D show the correlation between the measured PVS width and the 
measured vessel diameter. In many cases for smaller vessels, say less than 10 m, the 
perivascular space width is larger than the vessel diameter.  In a few cases, the 
perivascular space width is several times larger than the vessel diameter.  Even in 
these cases, the motion of nanoparticles in the perivascular space followed the 
contours of the blood vessel.  PVS width varied between 2 µm and 24 µm.  In 
addition, the annulus surrounding the vessel, in a large proportion of the vessels, was 
not uniform in width along the length of the vessel. In these cases, PVS width was 
measured at the widest part of the PVS along the vessel. This nonuniformity is likely 
due to unique anatomy in the neurovascular unit. Differences in this anatomy 
compared to unoccupied PVS in other local vessels could be indicators of why 
particular PVS are available to the particles, but were beyond the scope of our 
experiments.  
 Figure 3.6F-G show the velocities of nanoparticles in perivascular spaces as a 
function of the distance from the needle outlet to the point where the velocity is 
measured.  Most values of nanoparticle speeds are between 3 and 12 µm/s, although 
there are some nanoparticles that move considerably faster.  However, the figure 
shows that the speed of the nanoparticles does not appear to depend on distance from 
the infusion needle outlet.   
 Figure 3.6H-I show the velocities of nanoparticles in the perivascular space as 
a function of the width of the perivascular space where the velocity was measured. 
Most of the measured PVS widths fall between 1 and 10 µm, and the velocities are 
between 3 and 12 µm/s. The speeds of the 50 nm liposomes are higher than those of 
the other nanoparticles, confirming the higher average speed for the small liposomes 
shown in Figure 3.6E.  
 
3.3.6 Relative Volumes 
 
 Figure 3.7A-B show the measured PVS volumes in relation to distance from 
the needle outlet. PVS volume is the volume occupied by the infusate along the 
outside of blood vessels.  The equation used to calculate PVS volume was shown 
previously in this chapter. No trend was observed in this data. 
 Figure 3.7C-D show the measured PVS volumes as a function of PVS width. 
To better examine the relationship between the volumes of particles occupying local 
PVS to volume of particles in the parenchyma, we calculated the sum of PVS 
volumes, and divide it by the total volume of the distribution (spherical cloud volume 
and PVS volume). This gives us a better idea of the partitioning of the particles across 




show the average ratio of PVS volume to total volume of the distribution and PVS 
across all times for each particle type. On the left of the dividing line, the liposomes 
range from about 10% to 20% PVS volume to total volume. On the right of the line, 
the beads range from about 5% to 20% of the total volume. The liposomes do not 
seem to display a trend, and the 100 nm liposomes (bar 2) seem significantly higher 
than the other two liposome sizes. This is likely due to a lower number of observed 
PVS during these infusions. A higher proportion had higher PVS volume relative to 
the total volume, which can be seen in Figure 3.7F.  
 Figure 3.7F shows all the individual data points where PVS volume could be 
compared directly to the total volume for a volume sample. The smaller particles (size 
1 and 4 corresponding to 50 nm liposomes and 20 nm beads respectively) have smaller 
values for the PVS volume to total volume ratio, which is consistent with what is seen 
during the infusion. The volume of distribution is dominated by the particles in the 
parenchyma, or core of the cloud, at all time points, as there is less resistance to their 
movement in the ECS. As the particle size grows, a higher proportion of the particles 
from the infused volume move into perivascular routes instead of into parenchymal 
routes, increasing the value of the PVS volume to total volume. Figure 3.7G-H show 
the PVS volume to total volume ratio data vs. time. For the first few minutes in the 
infusions, it is possible for all the particles sizes to have between 20% and 80% of the 
total volume occupied be in the local PVS. There is a decrease in the PVS volume 
relative to total volume across all the particle sizes with time. There is great contrast in 
the way that the data points decrease for the different particle sizes. The smaller 
particles, shown in blue open and closed circles (50 nm liposomes and 20 nm beads 
respectively), drop off much quicker than the other particles. Due to the slower 
parenchymal velocity of the larger particles, the PVS to total volume ratio can stay 
between 1% and 10% past the 10-minute mark in some of the infusions for the 100 nm 
liposomes and the 100 and 200 nm beads. Figure 3.7I-J show where the PVS to total 
volume data lies relative to the volume of distribution of the parenchymal cloud. Most 
of the data falls along a decreasing band, as the PVS volume becomes significantly 
less than the cloud volume at longer times. Figures 3.7E-J demonstrate the relative 
effect that the local PVS have on the infusion, in that for sizes larger than around and 
greater than the average ECS pore size, a significant amount of the particles are 





To observe directly the difference between transport rates of nanoparticles and 
fluid during a CED infusion, a small molecule tracer (Cascade Blue dextran 3kDa) 
was infused at the same time with a suspension of 200 nm polystyrene nanoparticles. 
 shows a series of images from the infusion near the needle tip. The time 
intervals of the images are 32, 196, and 360 s after the start of the infusion.  At a time 
of 32 s, there is evidence that the dextran has entered the tissue, while the fluorescence 
of the nanoparticles appears to be confined to the needle lumen.  However, at a time of 
196 s extensive penetration of the dextran and the nanoparticles into the tissue is clear.  
At a time of 360 s, both the dextran and nanoparticles show increased penetration into  
  
the tissue.  At 196 and 360 s that the dextran has shown greater tissue penetration than 
the nanoparticles. 
nanopartic
value is higher than any of the values seen for the nanoparticles, this value signifies 
that the dextran traveled roughly 19% of the distance of an expanding sphere  
µ
where v(r) is the velocity as a function of radial position from the fluid source, Q is the 
volumetric flow rate for the fluid sou
and r is the radial position from the fluid source. For a direct comparison to the data 
d the velocity to be between 0.4 and 1 s, 
depending on the particle type (referring to Figure 3.5 for estimate). For most of our 
experiments, we observed nanoparticle movement, knowing that the fluid containing 
the nanoparticles should be moving at a different rate than the particles. To get a better 
understanding of relative velocity difference between the fluid and the nanoparticles, 
we infused a solution of the 200 nm nanoparticles with 3 kDa Cascade Blue dextran 
(1:3 nanoparticle solution to Cascade Blue dextran solution). Using three channels on 
the 2PEF setup, we could see the growth of both the small molecule (blue) and 
nanoparticle (red) clouds, as shown in . The blue cloud grows much 
quicker, and shows up near the edge of the field of view before the nanoparticles move 
Blue dextran is estimated to be is similar to the initial movement of 
other infusates. Furthermore, the fluid shows a drop in velocity similar to the 
nanoparticles, but it occurs at greater distances from the needle outlet. We chose the 
200 nm beads knowing that they would likely show the greatest difference in relative 
velocity. With smaller nanoparticles, the movement would approach fluid-like 
behavior. These differences in velocity play an important role in understanding drug-
delivery in vivo. With increased diameter of the infused material, moving the material 
from the infusion point in a CED situation becomes increasingly difficult, as the 
movement of the particles drops multiple orders of magnitude with increased radial 
position from the outlet of the infusion catheter. This limits the effective penetration 
distance of the larger particles for clinical purposes. The infusion rate could be 
increased to improve the penetration distance, but there is an upper limit to what can 
be achieved, depending on the catheter type. Ultimately, improvement of penetration 
distance and efficacy of the infused material will depend on other properties of the 
drug, if a larger particle size must be used for a particular treatment. 
Perivascular routes are believed to be highly permeable routes for fluid flow in 
the brain [45]. The velocity of fluid moving in these spaces surrounding blood vessels 
maximum distance traveled for dextrans in the brain by Carare et al. [77]. This differs 
by an order of magnitude from Foley et al. who approximated the velocity to be 25 
/s [45]. We found the average velocity of the various particle sizes to be between 6- 
. There is a slight decrease in PVS velocity for the 
increase in particle size, but it is not significant. The range of the data extended 
b  
may have been reasonable. With our extensive amount of infusions done, we could see 
the range of the PVS velocities, and estimate them in a more precise method. In 
comparison to relevant parenchymal velocity, the difference is greater. In 
and , we show the decrease in parenchymal velocity with increasing time. For most 
of the infusions, after an initial velocity of 0.5- locities drop to 
0.08-0.2 
the nanoparticles moving in the PVS can move two orders of magnitude than 
For 
which would allow for greater movement of the particles, and likely reduce any non-
specific binding effects of the particles to the ECS. The human brain also contains a 
larger volume of tissue than the rat brain that the particles would need to cover, and 
thus higher infusion volumes would be used. From our rat experiments, it seems that 
these particles are forced to move hindered through the ECS (prior to entering a PVS), 
which limits their use/efficacy. Long infusion times (order of hours) or other 
enhancement methods, such as focus ultrasound [48,78], would be necessary to 
increase the affected tissue. 
The resolution of our setup allows for unparalleled estimation of the volume 
occupied by particles compared to previous work done. With the higher resolution, we 
can see the presence of blood vessels and other unoccupied spaces within the tissue, 
allowing for better estimation of the real occupied volume relative to the infused 
volume. shows the average VD/VI ratio for each particle size. The 
magnitude of these values is multiple orders of magnitude less than tracer experiments 
that have been done for both brain phantoms and in vivo work in the past, and about 
an order of magnitude less than comparable work done with nanoparticles. Zhou et al. 
showed for PLGA nanoparticles of mean size 71 nm ± 13 nm and 147 nm ± 27 nm a 
VD/VI ratio of 3.7 ± 0.3 for trehalose coated particles, and 0.6 ± 0.1 for standard 
PLGA particles [56]. We showed average values between ~0.01 and 0.02. This means 
that the nanoparticles are extremely hindered once entering the brain tissue, and are 
only occupying roughly 10% the volume of a similar nanoparticle infused in a similar 
manner. The methods used for determining the volume of distribution in Zhou et al. 
involved both PET and post-mortem fluorescence imaging, which could help 
contribute to the order of magnitude difference in the ratio. It is intuitive that these 
particles would travel slower and occupy less space than a fluid-like tracer. There is a 
sharp drop between the 20 and 40 nm beads, and the 100 and 200 nm particles. We 
theorize that this is likely due to the mean ECS pore size being somewhere between 
these particle sizes, causing greater hindrance to the larger particle sizes. It is 
promising for clinical relevance that the 100 and 200 nm particles could move, albeit 
slowly, through the ECS. Furthermore, the liposomes of all sizes could occupy a larger 
volume of distribution than the beads for any size. This is likely due to the softer, 
more malleable nature of the liposome. The liposomes should be able to contort and 
pass through the tortuous ECS in a less-hindered manner than the rigid beads. If 
parenchymal delivery of a drug is desired, liposomes seem to offer advantages of both 
small molecules and modified nanoparticles in terms of transport. They are less 
hindered in the parenchyma, and can have their formulation modified to deliver 
specific concentration to specific areas in a local infusion. Liposomes are still 
susceptible to entering PVS, but as far as we can tell, anything introduced into the 
brain via a CED-like infusion can enter the PVS. 
In our investigation of perivascular velocity, we observed that cloud formation 
of the larger particles is influenced by the presence of local PVS. shows the 
influence that local PVS have on overall cloud growth for infusions for each particle 
size. We theorize that there is preferential movement of the particles in the direction of 
the PVS entrances due to higher convective currents in the brain, likely due to effects 
of a glymphatic system detailed by Iliff et al. [12]. While the conditions of the system 
are different (i.e. the dura has been breached), the presence of fast moving fluid 
pathways would have an effect similar to a fluid sink around the entrance to the PVS. 
More importantly, though, we have shown an important behavior that could lead to 
better targeting of drugs released in a CED-like infusion. By increasing the diameter 
of the infused particle to a size much larger than the mean ECS pore diameter, we 
increased the volume of particles in the PVS relative to the particles in the ECS at the 
same depth within the brain. This could have an impact on the way proliferating 
gliomas are treated. Migrating gliomas are known to use the PVS as means of 
expanding in rodent model, as the annular regions are adjacent to blood vessel walls, 
which can be sapped by the tumor cells to procure oxygen and nutrients without the 
need for vascularization [79,80]. We theorize that this may be the reason vascular 
endothelial growth inhibitors do not limit the expansion of migrating gliomas through 
the PVS. Our research would indicate that combinatorial treatments, potentially 
combining growth inhibitors for stopping the parenchymal tumors and larger particles 
to specifically eradicate perivascular tumor growth, may lead to more effective clinical 
treatment of gliomas. While research is done to improve penetration distance of 
nanoparticles in the parenchyma [29,46,56], we argue that there are several effective 
treatments for limiting/eliminating parenchymal tumors, and getting concentrated 
doses of cancer-killing drugs to the migrating perivascular tumors will have a large 
effect on the clinical outcome for the patient. 
In this work, we have presented an in depth look at nanoparticle dynamics 
introduced directly into the brain parenchyma of rats during a CED-like infusion. 
Through our experiments, we have elucidated quantitative features of rigid 
polystyrene beads and flexible liposomes, and theorized how these findings will 
benefit continuing clinical trials in the area. Fundamental understanding of the 
behavior of different infusates introduced during CED-like procedures leads to a better 
understanding of where the infusions will go during actual clinical practice, and 
control/predictability of this behavior is paramount to the goal of effective, targeted 
delivery in the treatment of neurological disorders. We give strong evidence that our 
method for predicting this behavior is significant in the field, as it allows for higher 
spatial and temporal resolution than any previous work has achieved for 
studying infused nanoparticle dynamics. With continual improvements in the 
technology, such as higher photon imaging modalities and more responsive setups, 
even higher resolution will be possible at greater depths within the brain, perhaps 
allowing for studies to be done in other sections of the brain outside of the cortex. 
Furthermore, with greater imaging depth, higher animal models could be used, such as 
porcine or primate, which would allow for testing of CED-like infusions closer to 
those done in humans. The method used would still be the same, but the experimental 
parameters, such as flow rate and size of needle used, could be augmented to resemble 









 Infusing therapeutic-like materials into gel phantoms that mimic live tissue 
properties plays an important early step in development of a treatment for treating 
CNS disorders. Finding materials that behave similar to live tissue and are robust, 
realistic, and cost-
standard for evaluating CED infusions in vitro. Chen et al. presented the similar 
characteristics between 0.6% agarose gels and pig brain tissue, as well as compared 
various infusion mediums for mimicking brain tissue [81]. In the following years, 
agarose gels became the standard for in vitro modeling for infusions in brain tissue, 
and was used for a variety of purposes. Hardy et al. investigated the VD/VI relationship 
for varied molecular weight tracers of gadolinium-tagged polylysine, finding a deep 
decrease as for higher molecular weight tracers [24]. Vazquez et al. evaluated 
polymer-coated cannulas that reduced backflow using agarose gels [82]. Casanova et 
al. looked at the relationship between needle insertion speed on the prevalence of 
backflow for varied needle sizes, and found that slower insertions into the agarose 
medium yielded larger backflow distances along the needle cannula [83]. Regardless 
of how well the agarose gel phantoms function as live tissue surrogates, they remain as 
an option for initial investigation of infusion parameters with certain therapeutics. 
 Both the brain microenvironment and tumor microenvironment present a 
complex challenge for the delivery of therapeutics. The tumor microenvironment has 
been shown to have lower mean ECS spacing than in normal tissue [40], leading to 
greater steric hindrance on the particles that approach the pore size. Increased 
concentration of agarose leads to decrease in pore size for the gel [84]. To gather 
insight into the movement of tracer particles near a tissue interface, we created an 
infusion setup that allowed us to infuse materials near the interface of agarose with 
conjugated albumin, penetrated significantly less into the higher concentration of 
agarose than in the lower concentration. The concentration of the tracer molecules 
dropped sharply at the interface of the two gel layers. Varied flow rates showed 
different concentration profiles for the infused tracer. While rigorous measurements 
were not made across a number of times of infusion, flow rates, and various infusates, 
the studies presented in this chapter allow for insights into the infusion near an agarose 
gel interface, which may influence in vivo studies near the edge of a particular region 
of the brain.  
 
4.2 Materials and Methods 
 
4.2.1 Agarose Gel Preparation 
 
For all weight percentages of agarose in water (0.2-0.6), agarose was measured out 
and added to volumetric flask or beaker. Solution was made by addition of distilled 
water. Agarose would not completely dissolve in the vessel, and thus heat was applied 
while the mixture was stirred. Temperature of the mixture was monitored via 
thermometer, as to not reach the boiling point. Once the solution became clear, 
indicating complete dissolution of the agarose, the vessel was removed from heat, and 
the stirring rod was removed. The mixture was then transferred to a custom plexiglass 
container while still at the high temperature. The vessel containing the initial, higher 
concentration layer of agarose was placed in a refrigerator to allow setting and 
hardening of the gel. The second layer could then be prepared using a similar method. 
Once the second layer solution was heated and ready to be poured, the first layer in the 
plexiglass container was removed from the refrigerator. The second, lower 
concentration layer was poured directly onto the first, higher concentration layer, and 
returned to the refrigerator to solidify. 
 
4.2.2 Infusion Setup 
 
The plexiglass container with multiple layers of agarose was moved to the area 
of an infusion pump. A capillary tube of 1 mm outer diameter (0.87 mm inner 
diameter) was lowered through a port in the roof of the plexiglass container into the 
agarose gel. Plastic tubing connected the capillary tube to a 3 mL screwtop syringe 
with an adaptor to feed the tubing into. An infusion pump (Harvard Apparatus 
various flow rates into the agarose gel. A picture of the experimental setup can be 
Figure 4.1.  
 
4.2.3 Concentration Determination of Standards 
 
To be able to estimate the concentration of EBD solution in the agarose once 
infused, a standard curve for the EBD was created. To do this, one-inch diameter clear 
plastic dishes were filled with 0.2% - 0.01% EBD solutions, and laid on a light source 
in an isolate
sample), angle (looking directly down at sample), and camera settings for each of the 
sample. The pictures were loaded into ImageJ, where a line was drawn across the 
center of the dish. The intensity profile for this line was averaged, giving a single 
value for the light intensity for each concentration of EBD solution.  
In our experiments, after infusion had occurred, we would cut out a rectangular 
cross section of the gel layers distributed evenly across the point of infusion. The 
thickness of the gel was similar to the depth of the dish used to create the standard 
curve, about 1 cm. The section of the gels would then be laid on the light source. 
Pictures were again taken in the manner in which the standard curve was generated. 
With the aid of the standard curve, we were able to translate the light intensity values 
from the gel section to estimates for the concentration of EBD in the gel at any point 
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 4.4 Discussion 
 
 Agarose gels provide a means of simulating brain tissue in vitro [24,78,81]. 
Through the use of agarose gels, initial characterization of an infusion setup can be 
performed. We used layered agarose to simulate an interface between two mediums 
with different mechanical characteristics. In general, these infusions behaved more 
isotropically into the agarose. The lack of blood vessels and other properties discussed 
in chapter 3 allows the infusion cloud morphology to become predictable. From these 
initial findings, we can influence translation to in vivo animal studies, and in theory, 
clinical trials. 
 Upon crossing the interface into the higher agarose concentration gel, the 
infusate experiences greater hindrance to movement, limiting its penetration further. 
The pressure gradient felt by the infusate near the interface is significantly less than 
near the needle outlet, but the immediate restraint shown between the horizontal 
expansion across the interface demonstrates this hindrance in Figure 4.3. In addition 
to loss in penetration depth, the concentration drops across the interface. Figures 4.5B 
and 4.6B both show a distinct drop in concentration near 1 cm on the cross section 
position. While concentration profiles are not discussed in detail in chapter 3 for the 
infusions (due to fluctuation in power levels in the imaging of the stacks), the images 
near the needle tip, for the smaller sizes of the polystyrene beads, displayed similar 
behavior to the lower flow rate data shown in Figure 4.6B. The concentration stayed 
at near max concentration until toward the edge of the cloud, where it dropped off 
rapidly. The infusions in the rat brain were done at lower flow rates than those done in 
the agarose gel, which may be necessary in reducing compression of the gel (or 
tissue), which could further restrict movement, as the average pore size will likely 






While agarose has many uses, and acts as a decent surrogate for brain tissue, it 
lacks the fine details and numerous additional complexities of real tissue. For the 
characterizing an 
infusion system, agarose can be appropriate. We showed a method of layering agarose 
gels for the purpose of creating an interface between the gels. Infusion near this 
interface may give indications as to what happens to therapeutics near a tissue 
interface in the brain. We showed that when a tracer molecule encounters an interface 
with a higher concentration of agarose, the movement slows down drastically, and the 
accumulation of tracer molecules in the higher agarose medium drops significantly 
from what is found in the lower concentration of agarose. This could have important 
implications when infusions are done near the interface between different sections of 
the brain in the treatment of various CNS afflictions, and needs to be taken into 
account when trying to develop a more effective treatment. 
 
CHAPTER 5 
CONCLUSIONS AND FUTURE WORK 
 
 This dissertation aims to give insight into the underlying mechanisms behind 
therapeutic transport in the brain. This is done through the development of a 
fluorescence imaging method for sampling the infusate volume with high spatial and 
temporal resolution. While our experiments do not allow for control over the infusate 
distribution during a convection-enhanced delivery, they do allow for better prediction 
of where therapeutics of various sizes and types will go during the infusion. We show 
how infusion behavior can be greatly influenced by the presence of perivascular 
spaces surrounding local blood vessels, and discuss how the presence of the spaces 
might influence therapeutic distribution in clinical practice. This final chapter will 
discuss the context of this work, and provide future direction for these studies. 
 In chapter 2, the development of our imaging system is discussed in detail, and 
we detail the process of gathering data, processing said data, and extracting 
quantitative features. The imaging setup involved opening a craniotomy in the skull of 
an anesthetized rat, placing the rat on a motorized stage beneath the two-photon optics, 
and imaging various depths within the cortex of the rat while the stage oscillated 
toward and away from the objective. This allowed for collection of emitted 
fluorescence from the entire infusion cloud as it was being infused. To the best of our 
knowledge, no other studies have attempted to image the micron-scale movements of 
infusates in the rat cortex in this fashion. Two-photon fluorescence imaging 
techniques have been used for imaging in other related studies [33,43]
the entire infusion cloud as it enters the tissue. Magnetic resonance imaging has been 
used to view entire infused volumes [30,60], but it lacks the resolution that we can 
achieve. Our imaging system is limited to the cortex, as this type of imaging does not 
allow for imaging beyond ~500 µm into the brain. Imaging infusions into other parts 
of the brain could reveal other behavior, but the technology is currently limited. 
Higher photon imaging modalities will allow for deeper imaging into the brain, but it 
may not be possible to image beyond a few microns with this technique. As MRI 
technology improves, it may become easier to image infusions into various parts of the 
brain with resolution similar to what we were able to achieve in the cortex.  
 In chapter 3, we discuss the imaging of various infusates using the two-photon 
imaging system developed in chapter 2. Therapeutics have been in development for 
uses in CNS disease, but the actual treatment of patients has not improved. We believe 
that this is due, in part, to incomplete understanding of the factors influencing infusion 
cloud growth during convection-enhanced delivery. With the two-photon imaging 
method described in chapter 2, we infused fluorescently-tagged polystyrene beads and 
fluorescent liposomes of various sizes below, around, and exceeding the size of the 
space between cells in the brain. 
 By watching the growth of the infusion cloud, we were able to view where the 
infusate went in real time. For smaller particles, the movement was less hindered by 
the size of the pores, leading to larger infusion clouds in shorter time spans. Larger 
particles experienced great resistance to movement, limiting their penetration into the 
tissue, even at long infusion times. The liposomes, even at larger sizes, were able to 
behave as though they were smaller, penetrating further into the tissue than their 
polystyrene bead counterparts. We catalogued all of the radial expansions and 
cloudfront velocities for each infusion, and fit this to power-law expressions from 
theory. Our results matched intuitively with what we predicted would happen, in that 
the flexibility of the liposomes allowed them to proliferate further into the tissue than 
their rigid polystyrene bead analogs. We compared these parenchymal transport rates 
to perivascular transport rates, which could be traced because we could see the 
progress of the infusate in perivascular spaces from our imaging. We found much 
higher movement speeds in the perivascular spaces than in the parenchyma, and the 
particles in the perivascular spaces moved within a 3-12 µm/s range for all particle 
sizes, which is consistent with values given in [85] for para-arterial drainage. 
Furthermore, there did not seem to be any effect of the pressure gradient from the 
needle outlet on the perivascular speed.  
We calculated the volume of infusate distributed in the parenchyma and the 
perivascular spaces. We found that, as particle size increased for both particle types, 
the volume of particles in the perivascular spaces relative to volume of particles in the 
parenchyma increased greatly. The larger particle sizes maintained a higher value of 
this ratio into the infusion, meaning that for infusions involving larger particles, the 
perivascular routes are allowing significant egress for the particles, which needs to be 
accounted for when performing convection-enhanced delivery in the clinic. In 
addition, we successfully co-infused a solution containing a smaller molecular weight 
dextran and 200 nm polystyrene beads. As expected, the dextran moved much further 
during the infusions than the polystyrene beads.  
These studies could be continued in a few directions. Experiments could be 
done to infuse larger polystyrene beads or liposomes into the rat cortex using the same 
imaging setup, in an attempt to find an upper limit for what could be infused into the 
parenchyma. Other nanoparticles could also be used. Co-infusions could be done with 
solutions containing multiple types of particles to see if similar partitioning behaviour 
can be achieved to what we saw with the dextran and polystyrene bead solution. 
Repeat experiments could be run for the infusates used, but a dye to label local 
astrocytes could also be applied so that we could observe what was occurring with the 
astrocytic endfeet near the perivascular entrances. This would give insight into 
conformational changes in the endfeet setup near the PVS entrance, perhaps indicating 
if they are acting as a gate or changing in position to allow more or less fluid to enter 
over time. 
Of particular interest to the author would be to use our system to do infusions 
with therapeutic like particles in the rat cortex with implanted tumor xenografts. The 
protocol for this system would take some time to develop, but something like what 
Baker et al. use in [86] would be a good starting point. The goal would be to see if the 
infusate acts different near or in the tumor xenograft, and if we could modulate the 
partitioning of the infusates to choose parenchyma or perivascular routes based on 
size, major breakthroughs in treating recurrent glioma could be achieved, at least in 
animal models. 
In chapter 4, we discuss a set of studies done with agarose gels of various 
concentrations. By layering the gels, and infusing near the interface of the layers, we 
can simulate the movement of therapeutics near a biological interface in vitro. While 
the setup is rather rudimentary, the ideas behind it could lead to more complexity if 
more studies were to be done. We captured infusion data for a few different gel layers 
and flow rates, and were able to back out the concentration profiles for the infusions. 
Our results indicated a drop in concentration across the gel interface, and the 
penetration into the higher concentration gel (lower porosity) was reduced for the dye 
used. If these experiments were to be continued, higher gradient in agarose 
concentration across the interface could be used to investigate larger hindrance on the 
infusate. More flow rates could be used, and repeat experiments could be used to 
gather statistical data for the preliminary data gathered here. Nanoparticles could be 
used, and co-infusions could be run, similar to those done in chapter 3, to see if a 
similar partitioning behavior can be achieved. 
  
APPENDIX 
CODE DEVELOPED FOR CALCULATING VARIOUS QUANTITATIVE 
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